Avidin participated in cystic fibrosis consortium meeting

Horizon 2020 Consortium meeting was held on Novel therapeutic approaches for the treatment of cystic fibrosis based on small molecule transmembrane anion transporters in Copenhagen, Denmark July 4-6 2017 .

The meeting of the Steering Committee has included the review of the project progress, milestones and planning of actions for the next six months together with the second TAT-CF Workshop.

Our screening development leader Dr. László Hackler presented the results of  end-point toxicity assays on Avidin’s newly synthetized 19 compounds in this last period. Lead compounds were further tested with Real time cell-electronic sensing and  Holographic microscopy.

Seminar title: Cellular screening technologies regarding to toxicity and side effects.